Severe asthma: What makes it so hard to manage?

Current Allergy and Asthma Reports

Volumn 9, Issue 5, 2009, Pages 393-400

  Carlstrom, Luke ^a   Castro, Mario ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CHEMOKINE RECEPTOR ANTAGONIST; CICLESONIDE; CLARITHROMYCIN; CORTICOSTEROID; CYCLOSPORIN; GOLD; HYDROCORTISONE; IMMUNOGLOBULIN; IMMUNOGLOBULIN E; INTERLEUKIN 5; ITRACONAZOLE; LIDOCAINE; LIPOXYGENASE INHIBITOR; LONG ACTING DRUG; MEPOLIZUMAB; METHOTREXATE; OMALIZUMAB; PREDNISOLONE; PROTON PUMP INHIBITOR; SALMETEROL; THEOPHYLLINE; TIOTROPIUM BROMIDE; TUMOR NECROSIS FACTOR ALPHA;

ADD ON THERAPY; BRONCHUS HYPERREACTIVITY; CLINICAL TRIAL; COMORBIDITY; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG HYPERSENSITIVITY; DRUG MEGADOSE; DRUG TREATMENT FAILURE; FORCED EXPIRATORY VOLUME; GASTROESOPHAGEAL REFLUX; HUMAN; HYPERTHERMIC THERAPY; IMMUNOMODULATION; INCIDENCE; LOW DRUG DOSE; MENTAL DISEASE; OBESITY; PATHOPHYSIOLOGY; PATIENT COMPLIANCE; PHENOTYPE; REVIEW; RHINITIS; SEVERE PERSISTENT ASTHMA; SKIN ALLERGY; SMOKING; UNSPECIFIED SIDE EFFECT;

ADRENAL CORTEX HORMONES; ANTI-ASTHMATIC AGENTS; ANTIBODIES, MONOCLONAL; ASTHMA; DIAGNOSIS, DIFFERENTIAL; HUMANS; IMMUNOLOGIC FACTORS; MEDICATION ADHERENCE; RISK FACTORS;

EID: 68949131162     PISSN: 15297322     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11882-009-0057-7     Document Type: Review

References (74)

1. The ENFUMOSA cross-sectional European multicentre study of the clinical phenotype of chronic severe asthma. European Network for Understanding Mechanisms of Severe Asthma. Eur Respir J 2003, 22:470-477.
2. Proceedings of the ATS workshop on refractory asthma: Current understanding, recommendations, and unanswered questions. American Thoracic Society. Am J Respir Crit Care Med 2000, 162:2341-2351.
3. Dolan CM, Fraher KE, Bleecker ER, et al.: Design and baseline characteristics of The Epidemiology and Natural History of Asthma: Outcomes and Treatment Regimens (TENOR) study: A large cohort of patients with severe or difficult-to-treat asthma. Ann Allergy Asthma Immunol 2004, 92:32-39.
4. Chung KF, Godard P, Adelroth E, et al.: Difficult/therapy-resistant asthma: The need for an integrated approach to define clinical phenotypes, evaluate risk factors, understand pathophysiology and find novel therapies. ERS Task Force on Difficult/Therapy-Resistant Asthma. European Respiratory Society. Eur Respir J 1999, 13:1198-1208.
5. Wenzel SE, Busse WW; the National Heart, Lung, and Blood Institute's Severe AsLhma Research Program: Severe asthma: lessons from the Severe Asthma Research Program. J Allergy Clin Immunol 2007, 119:14-21; quiz 22-23.
6. Taylor DR, Bateman ED, Boulet LP, et al.: A new perspective on concepts of asthma severity and control. Eur Respir J 2008, 32:545-554.
7. Bateman ED, Boushey HA, Bousquet J, et al.: Can guideline-defined asthma control be achieved? The Gaining Optimal Asthma Control study. Am J Respir Crit Care Med 2004, 170:836-844.
8. Heaney LG, Conway E, Kelly C, et al.: Predictors of therapy resistant asthma: Outcome of a systematic evaluation protocol. Thorax 2003, 58:561-566.
9. Robinson DS, Campbell DA, Durham SR, et al.: Systematic assessment of difficult-to-treat asthma. Eur Respir J 2003, 22:478-483.
10. Aburuz S, McElnay J, Millership J, et al.: Relationship between adherence to prescribed regimens and asthma control in patients with difficult asthma. Thorax 2002, 57(Suppl III):iIi89.
11. Akerman MJ, Calacanis CM, Madsen MK: Relationship between asthma severity and obesity. J Asthma 2004, 41:521-526.
12. Saint-Pierre P, Bourdin A, Chanez P, et al.: Are overweight asthmatics more difficult to control? Allergy 2006, 61:79-84.
13. Varraso R, Siroux V, Maccario J, et al.: Epidemiological Study on the Genetics and Environment of Asthma: Asthma severity is associated with body mass index and early menarche in women. Am J Respir Crit Care Med 2005, 171:334-339.
14. Haselkorn T, Fish JE, Chipps BE, et al.: Effect of weight change on asthma-related health outcomes in patients with severe or difficult-to-treat asthma. Respir Med 2009, 103:274-283.
15. van Veen IH, Ten Brinke A, Sterk PJ, et al.: Airway inflammation in obese and nonobese patients with difficult-to-treat asthma. Allergy 2008, 63:570-574.
16. Aaron SD, Fergusson D, Dent R, et al.: Effect of weight reduction on respiratory function and airway reactivity in obese women. Chest 2004, 125:2046-2052.
17. Hakala K, Stenius-Aarniala B, Sovijarvi A: Effects of weight loss on peak flow variability, airways obstruction, and lung volumes in obese patients with asthma. Chest 2000, 118:1315-1321.
18. Sutherland ER, Goleva E, Strand M, et al.: Body mass and glucocorticoid response in asthma. Am J Respir Crit Care Med 2008, 178:682-687.
19. Lee JH, Haselkorn T, Borish L, et al.: Risk factors associated with persistent airflow limitation in severe or difficult-to-treat asthma: insights from the TENOR study. Chest 2007, 132:1882-1889.
20. Chaudhuri R, Livingston E, McMahon AD, et al.: Effects of smoking cessation on lung function and airway inflammation in smokers with asthma. Am J Respir Crit Care Med 2006, 174:127-133.
21. Chalmers GW, Macleod KJ, Little SA, et al.: Influence of cigarette smoking on inhaled corticosteroid treatment in mild asthma. Thorax 2002, 57:226-230.
22. Chaudhuri R, Livingston E, McMahon AD, et al.: Cigarette smoking impairs the therapeutic response to oral corticosteroids in chronic asthma. Am J Respir Crit Care Med 2003, 168:1308-1311.
23. Pedersen B, Dahl R, Karlstrom R, et al.: Eosinophil and neutrophil activity in asthma in a one-year trial with inhaled budesonide. The impact of smoking. Am J Respir Crit Care Med 1996, 153:1519-1529.
24. ten Brinke A, Ouwerkerk ME, Bel EH, Spinhoven P: Similar psychological characteristics in mild and severe asthma. J Psychosom Res 2001, 50:7-10.
25. Campbell DA, Yellowlees PM, McLennan G, et al.: Psychiatric and medical features of near fatal asthma. Thorax 1995, 50:254-259.
26. Miles JF, Garden GM, Tunnicliffe WS, et al.: Psychological morbidity and coping skills in patients with brittle and non-brittle asthma: A case-control study. Clin Exp Allergy 1997, 27:1151-1159.
27. Kolbe J, Fergusson W, Vamos M, Garrett J: Case-control study of severe life threatening asthma (SLTA) in adults: Psychological factors. Thorax 2002, 57:317-322.
28. ten Brinke A, Ouwerkerk ME, Zwinderman AH, et al.: Psychopathology in patients with severe asthma is associated with increased health care utilization. Am J Respir Crit Care Med 2001, 163:1093-1096.
29. Heaney LG, Conway E, Kelly C, Gamble J: Prevalence of psychiatric morbidity in a difficult asthma population: Relationship to asthma outcome. Respir Med 2005, 99:1152-1159.
30. Leggett JJ, Johnston BT, Mills M, et al.: Prevalence of gastroesophageal reflux in difficult asthma: Relationship to asthma outcome. Chest 2005, 127:1227-1231.
31. ten Brinke A, Grootendorst DC, Schmidt JT, et al.: Chronic sinusitis in severe asthma is related to sputum eosinophilia. J Allergy Clin Immunol 2002, 109:621-626.
32. Ponte EV, Franco R, Nascimento HF, et al.: Lack of control of severe asthma is associated with co-existence of moderate-to-severe rhinitis. Allergy 2008, 63:564-569.
33. Mastronarde JG, Anthonisen NR, Castro M, et al.: Efficacy of esomeprazole for treatment of poorly controlled asthma: A randomized controlled trial. N Engl J Med 2009, 360:1487-1499.
34. Haldar P, Pavord ID, Shaw DE, et al.: Cluster analysis and clinical asthma phenotypes. Am J Respir Crit Care Med 2008, 178:218-224.
35. Haldar P, Pavord IA: Noneosinophilic asthma: a distinct clinical and pathologic phenotype. J Allergy Clin Immunol 2007, 119:1043-1052; quiz 1053-1054.
36. Wenzel SE, Schwartz LB, Langmack EL, et al.: Evidence that severe asthma can be divided pathologically into two inflammatory subtypes with distinct physiologic and clinical characteristics. Am J Respir Crit Care Med 1999, 160:1001-1008.
37. Miranda C, Busacker A, Balzar S, et al.: Distinguishing severe asthma phenotypes: Role of age at onset and eosinophilic inflammation. J Allergy Clin Immunol 2004, 113:101-108.
38. ten Brinke A, Zwinderman AH, Sterk PJ, et al.: Factors associated with persistent airflow limitation in severe asthma. Am J Respir Crit Care Med 2001, 164:744-748.
39. ten Brinke A, Zwinderman AH, Sterk PJ, et al.: "Refractory" eosinophilic airway inflammation in severe asthma: Effect of parenteral corticosteroids. Am J Respir Crit Care Med 2004, 170:601-605.
40. Bateman E, Karpel J, Casale T, et al.: Ciclesonide reduces the need for oral steroid use in adult patients with severe, persistent asthma. Chest 2006, 129:1176-1187.
41. Adcock IM, Caramori G, Chung KF: New targets for drug development in asthma. Lancet 2008, 372:1073-1087.
42. Usmani OS, Biddiscombe MF, Barnes PJ: Regional lung deposition and bronchodilator response as a function of beta2-agonist particle size. Am J Respir Crit Care Med 2005, 172:1497-1504.
43. Green RH, Brightling CE, McKenna S, et al.: Asthma exacerbations and sputum eosinophil counts: A randomised controlled trial. Lancet 2002, 360:1715-1721.
44. Silkoff PE, Lent AM, Busacker AA, et al.: Exhaled nitric oxide identifies the persistent eosinophilic phenotype in severe refractory asthma. J Allergy Clin Immunol 2005, 116:1249-1255.
45. van Veen IH, Sterk PJ, Schot R, et al.: Alveolar nitric oxide versus measures of peripheral airway dysfunction in severe asthma. Eur Respir J 2006, 27:951-956.
46. Berry M, Hargadon B, Morgan A, et al.: Alveolar nitric oxide in adults with asthma: Evidence of distal lung inflammation in refractory asthma. Eur Respir J 2005, 25:986-991.
47. Campbell JD, Borish L, Haselkorn T, et al.: The response to combination therapy treatment regimens in severe/difficult-to-treat asthma. Eur Respir J 2008, 32:1237-1242.
48. Bacci E, Cianchetti S, Bartoli M, et al.: Low sputum eosinophils predict the lack of response to beclomethasone in symptomatic asthmatic patients. Chest 2006, 129:565-572.
49. Green RH, Brightling CE, Woltmann G, et al.: Analysis of induced sputum in adults with asthma: Identification of subgroup with isolated sputum neutrophilia and poor response to inhaled corticosteroids. Thorax 2002, 57:875-879.
50. Pavord ID, Brightling CE, Woltmann G, Wardlaw AJ: Non-eosinophilic corticosteroid unresponsive asthma. Lancet 1999, 353:2213-2214.
51. Zacharasiewicz A, Wilson N, Lex C, et al.: Clinical use of noninvasive measurements of airway inflammation in steroid reduction in children. Am J Respir Crit Care Med 2005, 171:1077-1082.
52. Teeter JG, Bleecker ER: Relationship between airway obstruction and respiratory symptoms in adult asthmatics. Chest 1998, 113:272-277.
53. Ayres JG, Miles JF, Barnes PJ: Brittle asthma. Thorax 1998, 53:315-321.
54. Weiss ST, Van Natta ML, Zeiger RS: Relationship between increased airway responsiveness and asthma severity in the childhood asthma management program. Am J Respir Crit Care Med 2000, 162:50-56.
55. Josephs LK, Gregg I, Mullee MA, Holgate ST: Nonspecific bronchial reactivity and its relationship to the clinical expression of asthma. A longitudinal study. Am Rev Respir Dis 1989, 140:350-357.
56. Woolcock AJ, Salome CM, Yan K: The shape of the dose-response curve to histamine in asthmatic and normal subjects. Am Rev Respir Dis 1984, 130:71-75.
57. Lee P, Abisheganaden J,AChee CB, Wang YT: A new asthma severity index: a predictor of near-fatal asthma? Eur Respir J 2001, 18:272-278.
58. Gelb AF, Zamel N: Unsuspected pseudophysiologic emphysema in chronic persistent asthma. Am J Respir Crit Care Med 2000, 162:1778-1782.
59. Gelb AF, Schein A, Nussbaum E, et al.: Risk factors for near-fatal asthma. Chest 2004, 126:1138-1146.
60. Mauad T, Silva LF, Santos MA, et al.: Abnormal alveolar attachments with decreased elastic fiber content in distal lung in fatal asthma. Am J Respir Crit Care Med 2004, 170:857-862.
61. in't Veen JC, Beekman AJ, Bel EH, Sterk PJ: Recurrent exacerbations in severe asthma are associated with enhanced airway closure during stable episodes. Am J Respir Crit Care Med 2000, 161:1902-1906.
62. Bumbacea D, Campbell D, Nguyen L, et al.: Parameters associated with persistent airflow obstruction in chronic severe asthma. Eur Respir J 2004, 24:122-128.
63. Barnes PJ, Woolcock AJ: Difficult asthma. Eur Respir J 1998, 12:1209-1218.
64. Humbert M, Beasley R, Ayres J, et al.: Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE. Allergy 2005, 60:309-316.
65. Bousquet J, Cabrera P, Berkman N, et al.: The effect of treatment with omalizumab, an anti-IgE antibody, on asthma exacerbations and emergency medical visits in patients with severe persistent asthma. Allergy 2005, 60:302-308.
66. Denning DW, O'Driscoll BR, Hogaboam CM, et al.: The link between fungi and severe asthma: A summary of the evidence. Eur Respir J 2006, 27:615-626.
67. Denning DW, O'Driscoll BR, Powell G, et al.: Randomized controlled trial of oral antifungal treatment for severe asthma with fungal sensitization: The Fungal Asthma Sensitization Trial (FAST) study. Am J Respir Crit Care Med 2009, 179:11-18.
68. Dahlen SE, Malmstrom K, Nizankowska E, et al.: Improvement of aspirin-intolerant asthma by montelukast, a leukotriene antagonist: A randomized, double-blind, placebo-controlled trial. Am J Respir Crit Care Med 2002, 165:9-14.
69. Dahlen B, Nizankowska E, Szczeklik A, et al.: Benefits from adding the 5-lipoxygenase inhibitor zileuton to conventional therapy in aspirin-intolerant asthmatics. Am J Respir Crit Care Med 1998, 157:1187-1194.
70. Nair P, Pizzichini MM, Kjarsgaard M, et al.: Mepolizumab for prednisone-dependent asthma with sputum eosinophilia. N Engl J Med 2009, 360:985-993.
71. Simpson JL, Powell H, Boyle MJ, et al.: Clarithromycin targets neutrophilic airway inflammation in refractory asthma. Am J Respir Crit Care Med 2008, 177:148-155.
72. Qiu Y, Zhu J, Bandi V, et al.: Bronchial mucosal inflammation and upregulation of CXC chemoattractants and receptors in severe exacerbations of asthma. Thorax 2007, 62:475-482.
73. Fardon T, Haggart K, Lee DK, Lipworth BJ: A proof of concept study to evaluate stepping down the dose of fluticasone in combination with salmeterol and tiotropium in severe persistent asthma. Respir Med 2007, 101:1218-1228.
74. Pavord ID, Cox G, Thomson NC, et al.: Safety and efficacy of bronchial thermoplasty in symptomatic, severe asthma. Am J Respir Crit Care Med 2007, 176:1185-1191.